Biotechnology Innovation Organization

From Wikipedia, the free encyclopedia

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world that represents the biotechnology industry.[1][2][3] It was founded in 1993 as the Biotechnology Industry Organization, and changed its name to the Biotechnology Innovation Organization on January 4, 2016.[4][5] Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.[6]

Biotechnology Innovation Organization
Biotechnology innovation organization.png
NicknameBIO
Key people
Michelle McMurry-Heath (President & CEO, June 2020)
Websitehttps://www.bio.org/
Formerly called
Biotechnology Industry Organization

Activities[]

Trade meetings[]

BIO holds a trade meeting each year in the United States, which are essential for the business development and partnering activities that are required in the biotechnology sector, in which it is expensive to develop products, timelines to develop products are long, and regulatory risks are high.[7] In 2021 BIO Digital was held and was attended by just barely 6,000 delegates. This is far distant from the organization’s peak attendance of over 22,000 in Boston, 2007. They have not ever come close to that number since.

In 2021, the BIO reduced its in-person meetings from approximately 13 to 0 due to restrictions arising from the COVID-19 pandemic and staff layoffs. As of July 2021, no in-person meetings are scheduled to be held in 2021. [8]

Lobbying[]

In 2018, BIO spent $9.87 million on lobbying the government of the United States.[9] Past issues that BIO has lobbied on included the amending the Internal Revenue Code to provide an exception from the passive loss rules for investments in high-technology research small business pass-through entities, to include vaccines against seasonal influenza within the definition of taxable vaccines, and to extend, expand, and improve the qualifying therapeutic discovery project program that first became law in 2010.[10][11]

Examples of its public lobbying efforts, include support for development of biofuels such as those produced from algae,[12] genetically modified crops,[13] strong intellectual property rights,[14] and for a more efficient and predictable regulatory process for new food and drug products.[15]

Alliances[]

In June 2013 BIO partnered with the Coalition of Small Business Innovators to lobby the U.S. government to modernize the U.S. tax code "to recognize and promote small business innovation as fundamental to the long-term growth of the U.S. economy".[16][17]

It is a member of The Alliance to Feed the Future, an umbrella network, the mission of which is to "raise awareness and improve understanding of the benefits & necessity of modern food production and technology in order to meet global demand".[18][19]

Industry initiatives[]

The "Right Mix Matters" campaign launched in 2019 targets diversity within biopharmaceutical company leadership, including ongoing assessment of diversity measures (gender, race, ethnicity, sexual orientation) and the provision of online tools aimed at assisting companies to achieve target diversity goals.[5]

Organization[]

Members[]

BIOs members include companies that make Pharmaceutical drugs, biofuels, industrial enzymes, and genetically modified crops.[20] As of 2016, it represents 1,100 biotech companies in all 50 U.S. states, which employ 1.61 million Americans and support an additional 3.4 million jobs.[16]

Leadership[]

BIO was founded 1993 in Washington, D.C. and Carl B. Feldbaum was the president from BIO's founding until he retired in 2004.[21] He was succeeded by James C. Greenwood who held the offices of president and CEO from 2005 to 2020. Michelle McMurry-Heath became president and CEO as of 1 June 2020.[22]

Leadership of BIO is vested in a 100+ member board.[5] Ron Cohen, CEO of Acorda, was elected chair of the board in June 2015.[5] As of June 19, 2017, John Maraganore, PhD., president and chief executive officer of Alnylam Pharmaceuticals, Inc., was elected chair of the board.[23] As of June 4, 2019, Jeremy Levin, CEO of Ovid Therapeutics, was elected board chair.[24]

Biotechnology Heritage Award[]

The Biotechnology Heritage Award, presented annually at the Biotechnology Innovation Organization (BIO) Annual International Convention by the Biotechnology Innovation Organization (BIO) and the Science History Institute (formerly the Chemical Heritage Foundation), recognizes individuals who have made significant contributions to the development of biotechnology through discovery, innovation, and public understanding.[25]

References[]

  1. ^ Anna Edney, "Biosciences Defy U.S. Jobs Slump as Research Labs Hire", Bloomberg News, June 19, 2012.
  2. ^ European Biotechnology Network. "List of European and International Biotech Industry Associations" Archived 2019-01-29 at the Wayback Machine
  3. ^ "GEN's 30th Anniversary: Biotech Trade Associations", Genetic Engineering News, June 15, 2011.
  4. ^ "Biotechnology Innovation Organization changes name to Biotechnology Innovation Organization" (Press release). BusinessWire. 4 January 2016. Retrieved 4 July 2019.
  5. ^ Jump up to: a b c d Wright, Rob (1 July 2019). "Increasing Diversity Among Leadership And Boards". Life Science Leader. VertMarkets.
  6. ^ "About BIO". diapharma. June 2017. Retrieved 22 May 2020.
  7. ^ Robert Weisman, "Biopharmaceutical industry faces a shift in dynamics", Boston Globe, April 23, 2013.
  8. ^ "BIO lays off staff to adapt to another year of virtual events". FierceBiotech. Retrieved 2021-01-25.
  9. ^ Staff, The Center for Responsive Politics. "Lobbying: Biotechnology Innovation Organization", Page Accessed January 2, 2020
  10. ^ The Center for Responsive Politics, "Bills lobbied", Page Accessed June 7, 2013
  11. ^ Drew Armstrong, "Promising' Biotechnology Medicines May Earn $5 Million U.S. Tax Credit", Bloomberg News, May 21, 2010.
  12. ^ Kambiz Foroohar for Bloomberg News. June 3, 2010. Exxon $600 Million Algae Investment Makes Khosla See Pipe Dream
  13. ^ Elaine Watson, "It's not too late to change the conversation on GMOs: Interview with Cathy Enright, Executive VP for Food and Biotechnology, BIO", Food Navigator, May 20, 2013.
  14. ^ Victoria Slind-Flor, "LG, DuPont, Bank of America, GM: Intellectual Property", Bloomberg News, December 3, 2012.
  15. ^ Robert Weisman, "Federal drug review nettles biotech industry", Boston Globe, June 19, 2012.
  16. ^ Jump up to: a b "Biotechnology Innovation Organization Joins Coalition of Small Business Innovators" Archived 2014-11-04 at the Wayback Machine, BIO Press Release, June 4, 2013.
  17. ^ "Coalition of Small Business Innovators Official Website". Archived from the original on 2017-09-30. Retrieved 2016-01-04.
  18. ^ Alliance to Feed the Future Official Website Archived May 11, 2013, at the Wayback Machine
  19. ^ PR Web. Monday, March 18, 2013 "Alliance to Feed the Future Congratulates Our Farmers, Supports Education for Future Generations on National Agriculture Day"
  20. ^ "BIO profile at Biospace". Archived from the original on 2017-10-13. Retrieved 2016-01-04.
  21. ^ "BIO President Carl Feldbaum to Retire at Year End" (Press release). Biotechnology Innovation Organization. 2 February 2004. Retrieved 15 July 2009.
  22. ^ "BIO Appoints a Physician-Scientist as New President and CEO". BusinessWire. May 14, 2020. Retrieved 19 May 2020.
  23. ^ "BIO Elects John Maraganore, Ph.D., as New Chair". BIO. June 19, 2017. Retrieved 19 May 2020.
  24. ^ "BIO Elects Dr. Jeremy Levin as New Board Chair". BIO. June 4, 2019. Retrieved 19 May 2020.
  25. ^ "Biotechnology Heritage Award". Science History Institute. Retrieved 21 February 2018.

External links[]

Retrieved from ""